Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.

Literature DB >> 31558475

T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.

Natalia Lapteva^1,2, Margaret Gilbert¹, Iulia Diaconu¹, Lisa A Rollins¹, Mina Al-Sabbagh¹, Swati Naik^1,3,4, Robert A Krance^1,3,4, Tamara Tripic¹, Manasa Hiregange¹, Darshana Raghavan¹, Olga Dakhova¹, Rayne H Rouce^1,3,4, Hao Liu^1,5, Bilal Omer^1,3,4, Barbara Savoldo^1,3, Gianpietro Dotti^1,2,6, Conrad Russel Cruz¹, Keli Sharpe¹, Melissa Gates¹, Aaron Orozco¹, April Durett¹, Elizabeth Pacheco¹, Adrian P Gee^1,3, Carlos A Ramos^1,6,7, Helen E Heslop^1,3,4,6,7, Malcolm K Brenner^1,3,4,6,7, Cliona M Rooney^8,2,3,4,9,10.

Abstract

PURPOSE: Current protocols for CD19 chimeric antigen receptor-expressing T cells (CD19.CAR-T cells) require recipients to tolerate preinfusion cytoreductive chemotherapy, and the presence of sufficient target antigen on normal or malignant B cells. PATIENTS AND METHODS: We investigated whether additional stimulation of CD19.CAR-T cells through their native receptors can substitute for cytoreductive chemotherapy, inducing expansion and functional persistence of CD19.CAR-T even in patients in remission of B-cell acute lymphocytic leukemia. We infused a low dose of CD19.CAR-modified virus-specific T cells (CD19.CAR-VST) without prior cytoreductive chemotherapy into 8 patients after allogeneic stem cell transplant.
RESULTS: Absent virus reactivation, we saw no CD19.CAR-VST expansion. In contrast, in patients with viral reactivation, up to 30,000-fold expansion of CD19.CAR-VSTs was observed, with depletion of CD19+ B cells. Five patients remain in remission at 42-60+ months.
CONCLUSIONS: Dual T-cell receptor and CAR stimulation can thus potentiate effector cell expansion and CAR-target cell killing, even when infusing low numbers of effector cells without cytoreduction. ©2019 American Association for Cancer Research.

Entities: Chemical

Mesh：

Substances：

Year: 2019 PMID： 31558475 PMCID： PMC7062259 DOI： 10.1158/1078-0432.CCR-18-3199

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

30 in total

1. Early and late hematologic toxicity following CD19 CAR-T cells.

Authors: Shalev Fried; Abraham Avigdor; Bella Bielorai; Amilia Meir; Michal J Besser; Jacob Schachter; Avichai Shimoni; Arnon Nagler; Amos Toren; Elad Jacoby
Journal: Bone Marrow Transplant Date: 2019-02-26 Impact factor: 5.483

2. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma.

Authors: I C Nicholson; K A Lenton; D J Little; T Decorso; F T Lee; A M Scott; H Zola; A W Hohmann
Journal: Mol Immunol Date: 1997 Nov-Dec Impact factor: 4.407

3. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Authors: Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney
Journal: J Clin Invest Date: 2016-04-25 Impact factor: 14.808

4. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

Authors: James N Kochenderfer; Mark E Dudley; Robert O Carpenter; Sadik H Kassim; Jeremy J Rose; William G Telford; Frances T Hakim; David C Halverson; Daniel H Fowler; Nancy M Hardy; Anthony R Mato; Dennis D Hickstein; Juan C Gea-Banacloche; Steven Z Pavletic; Claude Sportes; Irina Maric; Steven A Feldman; Brenna G Hansen; Jennifer S Wilder; Bazetta Blacklock-Schuver; Bipulendu Jena; Michael R Bishop; Ronald E Gress; Steven A Rosenberg
Journal: Blood Date: 2013-09-20 Impact factor: 22.113

5. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Authors: Andras Heczey; Chrystal U Louis; Barbara Savoldo; Olga Dakhova; April Durett; Bambi Grilley; Hao Liu; Mengfeng F Wu; Zhuyong Mei; Adrian Gee; Birju Mehta; Huimin Zhang; Nadia Mahmood; Haruko Tashiro; Helen E Heslop; Gianpietro Dotti; Cliona M Rooney; Malcolm K Brenner
Journal: Mol Ther Date: 2017-06-09 Impact factor: 11.454

6. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Authors: Michael Hudecek; Daniel Sommermeyer; Paula L Kosasih; Anne Silva-Benedict; Lingfeng Liu; Christoph Rader; Michael C Jensen; Stanley R Riddell
Journal: Cancer Immunol Res Date: 2014-09-11 Impact factor: 11.151

7. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Authors: Ifigeneia Tzannou; Anastasia Papadopoulou; Swati Naik; Kathryn Leung; Caridad A Martinez; Carlos A Ramos; George Carrum; Ghadir Sasa; Premal Lulla; Ayumi Watanabe; Manik Kuvalekar; Adrian P Gee; Meng-Fen Wu; Hao Liu; Bambi J Grilley; Robert A Krance; Stephen Gottschalk; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Ann M Leen; Bilal Omer
Journal: J Clin Oncol Date: 2017-08-07 Impact factor: 44.544

8. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.

Authors: Jiali Sun; Leslie E Huye; Natalia Lapteva; Maksim Mamonkin; Manasa Hiregange; Brandon Ballard; Olga Dakhova; Darshana Raghavan; April G Durett; Serena K Perna; Bilal Omer; Lisa A Rollins; Ann M Leen; Juan F Vera; Gianpietro Dotti; Adrian P Gee; Malcolm K Brenner; Douglas G Myers; Cliona M Rooney
Journal: J Immunother Cancer Date: 2015-02-18 Impact factor: 13.751

9. Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells.

Authors: Bilal Omer; Paul A Castillo; Haruko Tashiro; Thomas Shum; Mai T A Huynh; Mara Cardenas; Miyuki Tanaka; Andrew Lewis; Tim Sauer; Robin Parihar; Natalia Lapteva; Michael Schmueck-Henneresse; Malini Mukherjee; Stephen Gottschalk; Cliona M Rooney
Journal: Front Med (Lausanne) Date: 2018-12-11

10. Influence of FcgammaRIIA and MBL polymorphisms on severe acute respiratory syndrome.

Authors: F F Yuan; J Tanner; P K S Chan; S Biffin; W B Dyer; A F Geczy; J W Tang; D S C Hui; J J Y Sung; J S Sullivan
Journal: Tissue Antigens Date: 2005-10

12 in total

1. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.

Authors: Jaitip Tipanee; Ermira Samara-Kuko; Thierry Gevaert; Marinee K Chuah; Thierry VandenDriessche
Journal: Mol Ther Date: 2022-06-16 Impact factor: 12.910

2. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.

Authors: Laura Evgin; Tim Kottke; Jason Tonne; Jill Thompson; Amanda L Huff; Jacob van Vloten; Madelyn Moore; Josefine Michael; Christopher Driscoll; Jose Pulido; Eric Swanson; Richard Kennedy; Matt Coffey; Houra Loghmani; Luis Sanchez-Perez; Gloria Olivier; Kevin Harrington; Hardev Pandha; Alan Melcher; Rosa Maria Diaz; Richard G Vile
Journal: Sci Transl Med Date: 2022-04-13 Impact factor: 19.319

Review 3. Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.

Authors: Helen E Heslop; Sandhya Sharma; Cliona M Rooney
Journal: J Clin Oncol Date: 2021-01-12 Impact factor: 44.544

4. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.

Authors: Dana Stenger; Tanja A Stief; Theresa Kaeuferle; Semjon Willier; Felicitas Rataj; Kilian Schober; Binje Vick; Ramin Lotfi; Beate Wagner; Thomas G P Grünewald; Sebastian Kobold; Dirk H Busch; Irmela Jeremias; Franziska Blaeschke; Tobias Feuchtinger
Journal: Blood Date: 2020-09-17 Impact factor: 22.113

Review 5. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.

Authors: Cynthia Perez; Isabelle Gruber; Caroline Arber
Journal: Front Immunol Date: 2020-11-11 Impact factor: 7.561

Review 6. T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies.

Authors: Valérie Janelle; Jean-Sébastien Delisle
Journal: Cancers (Basel) Date: 2021-02-03 Impact factor: 6.639

7. Large-scale manufacturing and characterization of CMV-CD19CAR T cells.

Authors: Xiuli Wang; Ryan Urak; Miriam Walter; Min Guan; Tianxu Han; Vibhuti Vyas; Sheng-Hsuan Chien; Brenna Gittins; Mary C Clark; Sally Mokhtari; Angelo Cardoso; Don J Diamond; John Zaia; Stephen J Forman; Ryotaro Nakamura
Journal: J Immunother Cancer Date: 2022-01 Impact factor: 13.751